This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Role of biomarkers in diagnosis and evaluation of disease activity of Crohn's disease
Yi Zhang, Pei-Xue Wang, Hong-Jie Zhang
Yi Zhang, Pei-Xue Wang, Hong-Jie Zhang, Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), Nanjing 210029, Jiangsu Province, China
Correspondence to: Hong-Jie Zhang, Professor, Chief Physician, Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), 300 Guangzhou Road, Nanjing 210029, Jiangsu Province, China. hjzhang06@163.com
Received: August 27, 2016 Revised: September 14, 2016 Accepted: September 25, 2016 Published online: November 18, 2016
Crohn's disease (CD) is a group of chronic, relapsing inflammatory gastrointestinal diseases with unknown etiology. The goals of treatment are to induce the transition from active stage into inactive stage and to maintain remission. Therefore, it is important to diagnose and assess disease activity in patients with CD. Recently, noninvasive markers for intestinal inflammation have been wildly adopted in clinical practice in order to differentiate CD from other diseases, to grade inflammation, to assess the response to therapy, and to demonstrate recurrent inflammation after medical or surgically-induced remission. Fecal and serum calprotectins are among the best-studied noninvasive biomarkers of inflammation in CD which have attracted clinicians' attention. This paper gives an overview of the clinical implications of biomarkers for diagnosing and monitoring disease activity of CD.
Citation: Zhang Y, Wang PX, Zhang HJ. Role of biomarkers in diagnosis and evaluation of disease activity of Crohn's disease. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4389-4395
Eugene C. The second European evidence-based consensus on the diagnosis and management of Crohn's disease (part 3).Clin Res Hepatol Gastroenterol. 2011;35:516-517.
[PubMed] [DOI]
Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis.J Crohns Colitis. 2010;4:7-27.
[PubMed] [DOI]
Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens.Gastroenterology. 2002;123:689-699.
[PubMed] [DOI]
Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.Inflamm Bowel Dis. 2009;15:365-374.
[PubMed] [DOI]
Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.Gastroenterology. 2006;131:366-378.
[PubMed] [DOI]
Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.Gastroenterology. 2005;128:2020-2028.
[PubMed] [DOI]
Xiong Y, Wang GZ, Zhou JQ, Xia BQ, Wang XY, Jiang B. Serum antibodies to microbial antigens for Crohn's disease progression: a meta-analysis.Eur J Gastroenterol Hepatol. 2014;26:733-742.
[PubMed] [DOI]
Yang DH, Yang SK, Park SH, Lee HS, Boo SJ, Park JH, Na SY, Jung KW, Kim KJ, Ye BD. Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease.Gut Liver. 2015;9:80-86.
[PubMed] [DOI]
Boschetti G, Laidet M, Moussata D, Stefanescu C, Roblin X, Phelip G, Cotte E, Passot G, Francois Y, Drai J. Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease.Am J Gastroenterol. 2015;110:865-872.
[PubMed] [DOI]
Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, Seidel L, Colombel JF, Louis E. Serum calprotectin as a biomarker for Crohn's disease.J Crohns Colitis. 2013;7:e678-e683.
[PubMed] [DOI]
Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease.Inflamm Bowel Dis. 2004;10:661-665.
[PubMed] [DOI]
Sajjadi M, Gholamrezaei A, Daryani NE. No association between serum adenosine deaminase activity and disease activity in Crohn's disease.Dig Dis Sci. 2015;60:1755-1760.
[PubMed] [DOI]
Tang J, Gao X, Zhi M, Zhou HM, Zhang M, Chen HW, Yang QF, Liang ZZ. Plateletcrit: a sensitive biomarker for evaluating disease activity in Crohn's disease with low hs-CRP.J Dig Dis. 2015;16:118-124.
[PubMed] [DOI]
Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, Varga E, Szathmari M, Lakatos PL. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?Inflamm Bowel Dis. 2012;18:1647-1654.
[PubMed] [DOI]
Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.J Crohns Colitis. 2015;9:525-531.
[PubMed] [DOI]
Nakarai A, Kato J, Hiraoka S, Inokuchi T, Takei D, Morito Y, Akita M, Takahashi S, Hori K, Harada K. Slight increases in the disease activity index and platelet count imply the presence of active intestinal lesions in C-reactive protein-negative Crohn's disease patients.Intern Med. 2014;53:1905-1911.
[PubMed] [DOI]
Sobolewska A, Włodarczyk M, Stec-Michalska K, Fichna J, Wiśniewska-Jarosińska M. Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study.Dig Dis Sci. 2016;61:542-549.
[PubMed] [DOI]
Takeyama H, Mizushima T, Iijima H, Shinichiro S, Uemura M, Nishimura J, Hata T, Takemasa I, Yamamoto H, Doki Y. Platelet Activation Markers Are Associated with Crohn's Disease Activity in Patients with Low C-Reactive Protein.Dig Dis Sci. 2015;60:3418-3423.
[PubMed] [DOI]
Yılmaz B, Köklü S, Yüksel O, Arslan S. Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease.World J Gastroenterol. 2014;20:10916-10920.
[PubMed] [DOI]
La Montagna G, Parenti M, Oliani C, Filippi F, Tirri G. [Beta-cyclodextrin-piroxicam in the treatment of the active phase of osteoarthritic pathology].Riv Eur Sci Med Farmacol. 1990;12:265-272.
[PubMed] [DOI]
Gecse KB, Brandse JF, van Wilpe S, Löwenberg M, Ponsioen C, van den Brink G, D'Haens G. Impact of disease location on fecal calprotectin levels in Crohn's disease.Scand J Gastroenterol. 2015;50:841-847.
[PubMed] [DOI]
Cerrillo E, Beltrán B, Pous S, Echarri A, Gallego JC, Iborra M, Pamies J, Nos P. Fecal Calprotectin in Ileal Crohn's Disease: Relationship with Magnetic Resonance Enterography and a Pathology Score.Inflamm Bowel Dis. 2015;21:1572-1579.
[PubMed] [DOI]
Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, Hu PJ, Chen MH. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies.Inflamm Bowel Dis. 2012;18:1894-1899.
[PubMed] [DOI]
Qiu Y, Mao R, Chen BL, He Y, Zeng ZR, Xue L, Song XM, Li ZP, Chen MH. Fecal calprotectin for evaluating postoperative recurrence of Crohn's disease: a meta-analysis of prospective studies.Inflamm Bowel Dis. 2015;21:315-322.
[PubMed] [DOI]
Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, Leach S, Gorelik A, Liew D, Prideaux L. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.Gastroenterology. 2015;148:938-947.e1.
[PubMed] [DOI]
Boschetti G, Garnero P, Moussata D, Cuerq C, Préaudat C, Duclaux-Loras R, Mialon A, Drai J, Flourié B, Nancey S. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.Inflamm Bowel Dis. 2015;21:331-336.
[PubMed] [DOI]
Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Keenan JI, Leach S, Burgess L, Aitchison A, Gorelik A. Comparison of Fecal Inflammatory Markers in Crohn's Disease.Inflamm Bowel Dis. 2016;22:1086-1094.
[PubMed] [DOI]
Klimczak K, Lykowska-Szuber L, Eder P, Krela-Kazmierczak I, Stawczyk-Eder K, Szymczak A, Michalak M, Studniarek A, Linke K. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity.Eur J Intern Med. 2015;26:623-627.
[PubMed] [DOI]
Gisbert JP, Bermejo F, Pérez-Calle JL, Taxonera C, Vera I, McNicholl AG, Algaba A, López P, López-Palacios N, Calvo M. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.Inflamm Bowel Dis. 2009;15:1190-1198.
[PubMed] [DOI]
Nancey S, Boschetti G, Moussata D, Cotte E, Peyras J, Cuerq C, Haybrard J, Charlois AL, Mialon A, Chauvenet M. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.Inflamm Bowel Dis. 2013;19:1043-1052.
[PubMed] [DOI]
Husain N, Tokoro K, Popov JM, Naides SJ, Kwasny MJ, Buchman AL. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis.J Clin Gastroenterol. 2013;47:246-251.
[PubMed] [DOI]
Biancone L, Fantini M, Tosti C, Bozzi R, Vavassori P, Pallone F. Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum.Eur J Gastroenterol Hepatol. 2003;15:261-266.
[PubMed] [DOI]
Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage.Gut. 2009;58:859-868.
[PubMed] [DOI]
Czub E, Nowak JK, Szaflarska-Poplawska A, Grzybowska-Chlebowczyk U, Landowski P, Moczko J, Adamczak D, Mankowski P, Banasiewicz T, Plawski A. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity.Acta Biochim Pol. 2014;61:99-102.
[PubMed] [DOI]
Day AS, Judd T, Lemberg DA, Leach ST. Fecal M2-PK in children with Crohn's disease: a preliminary report.Dig Dis Sci. 2012;57:2166-2170.
[PubMed] [DOI]
Horjus CS, van Oijen MG, Davids AH, Naber AH, de Jong DJ. Microalbuminuria is not a valuable marker for relapse in Crohn's disease.Digestion. 2011;83:41-45.
[PubMed] [DOI]
Markó L, Szigeti N, Szabó Z, Böddi K, Takátsy A, Ludány A, Koszegi T, Molnár GA, Wittmann I. Potential urinary biomarkers of disease activity in Crohn's disease.Scand J Gastroenterol. 2010;45:1440-1448.
[PubMed] [DOI]